Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
1 day ago · Today's Change. (-3.76%) -$2.37. Current Price. $60.60. Price as of November 12, 2024, 4:00 p.m. ET. Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry ...
Viking Therapeutics, Inc. (VKTX) Latest Stock News & Headlines …
Get the latest Viking Therapeutics, Inc. (VKTX) stock news and headlines to help you in your trading and investing decisions.
Viking Therapeutics Reports New Data from VK2735 Obesity …
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations ...
Viking Therapeutics - Press Releases
News & Events. Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Viking Therapeutics’ stock soars 18% as data on oral weight-loss …
Oct 24, 2024 · Viking Therapeutics Inc.’s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted...
Viking Therapeutics Announces Results from Phase 1b Clinical …
Oct 9, 2024 · Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today...
News & Events - Viking Therapeutics InvestorRoom
Feb 27, 2024 · Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity. Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo.
Viking Therapeutics to Present Data from Phase 2b VOYAGE …
2 days ago · --Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the ...
Viking Therapeutics to Present Data from Phase 2b VOYAGE …
2 days ago · Results to be Featured in Oral Late Breaker Presentation. SAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company ...
Viking Therapeutics' weight-loss pill shows 'great outcome' in trial
Nov 4, 2024 · Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The news sent the stock ...